Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 523,367 | 449,375 | 347,099 | 85,201 | 447,098 |
| Depreciation Amortization | 370,156 | 226,624 | 147,939 | 14,672 | 260,691 |
| Income taxes - deferred | -236,610 | -167,935 | -151,347 | -17,053 | -88,815 |
| Accounts receivable | -92,326 | -4,307 | -47,574 | -56,960 | -40,132 |
| Accounts payable and accrued liabilities | 4,770 | 29,104 | -14,096 | 1,554 | 17,040 |
| Other Working Capital | -154,173 | -16,271 | -108,256 | -20,797 | 21,083 |
| Other Operating Activity | 361,217 | 172,013 | 177,335 | 195,636 | 181,939 |
| Operating Cash Flow | $776,401 | $688,603 | $351,100 | $202,253 | $798,904 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 67,900 | 234,025 | 269,025 | -115,000 | -310,915 |
| PPE Investments | -25,926 | -32,998 | -21,911 | -7,948 | 27,528 |
| Net Acquisitions | -55,074 | -55,074 | N/A | N/A | N/A |
| Sale Of Investment | N/A | N/A | N/A | 345,000 | N/A |
| Purchase Sale Intangibles | -142,200 | -142,200 | -83,700 | -56,000 | -111,100 |
| Other Investing Activity | -142,200 | -142,200 | -83,700 | -56,000 | -111,100 |
| Investing Cash Flow | $-155,300 | $3,753 | $163,414 | $166,052 | $-394,487 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -33,387 | -25,040 | -16,693 | -8,347 | -25,717 |
| Common Stock Issued | 57,831 | 26,090 | 16,122 | 3,057 | 93,337 |
| Common Stock Repurchased | -301,450 | -191,115 | -171,118 | -111,249 | -523,672 |
| Other Financing Activity | -16,739 | -15,900 | -14,813 | -13,810 | -23,078 |
| Financing Cash Flow | $-293,745 | $-205,965 | $-186,502 | $-130,349 | $-479,130 |
| Exchange Rate Effect | 366 | -838 | 105 | -112 | -1,700 |
| Beginning Cash Position | 309,622 | 309,622 | 309,622 | 309,622 | 386,035 |
| End Cash Position | 637,344 | 795,175 | 637,739 | 547,466 | 309,622 |
| Net Cash Flow | $327,722 | $485,553 | $328,117 | $237,844 | $-76,413 |
| Free Cash Flow | |||||
| Operating Cash Flow | 776,401 | 688,603 | 351,100 | 202,253 | 798,904 |
| Capital Expenditure | -40,135 | -32,998 | -21,911 | -7,948 | -20,370 |
| Free Cash Flow | 736,266 | 655,605 | 329,189 | 194,305 | 778,534 |